Evidence map›Paper›PMID 37141254›Full record

ArticleeLife2023

Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis.

Pierre Dupuy, Shreya Ghosh, Allison Fay, Oyindamola Adefisayo, Richa Gupta, Stewart Shuman, Michael S Glickman

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Journal of bacteriology · 2026
    Review
  3. Review
  4. Article
  5. Expression ofFrontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Pierre Dupuy *Immunology Program, Sloan Kettering Institute, New York, United States.ORCID 0000-0002-7451-304X
Shreya Ghosh *Molecular Biology Program, Sloan Kettering Institute, New York, United States.
Allison FayImmunology Program, Sloan Kettering Institute, New York, United States.
Oyindamola AdefisayoImmunology Program, Sloan Kettering Institute, New York, United States.ORCID 0000-0001-9376-148X
Richa GuptaImmunology Program, Sloan Kettering Institute, New York, United States.
Stewart ShumanMolecular Biology Program, Sloan Kettering Institute, New York, United States.
Michael S GlickmanImmunology Program, Sloan Kettering Institute, New York, United States.ORCID 0000-0001-7918-5164
Kettering University · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Novel pathway of DNA inter-strand crosslink repair in mycobacteriaR01AI064693 · NIAID · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael S Glickman, Stewart H Shuman · 2005 to 2026
$11.1M
NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI064693
6 · The paper itself

Abstract

Translesion synthesis by translesion polymerases is a conserved mechanism of DNA damage tolerance. In bacteria, DinB enzymes are the widely distributed promutagenic translesion polymerases. The role of DinBs in mycobacterial mutagenesis was unclear until recent studies revealed a role for mycobacterial DinB1 in substitution and frameshift mutagenesis, overlapping with that of translesion polymerase DnaE2.

Indexed as

Frameshift MutationMycobacterium tuberculosisBacterial ProteinsDNA RepairMutagenesisBacterial Proteinsantimicrobial resistanceDNA damage responseinfectious diseasemicrobiologymutagenesisMycobacterium smegmatisMycobacterium tuberculoiss

Identifiers

PMID37141254
PMCPMC10159617
OpenAlexW4368355647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.